News Business Medical Research
Avicanna’s proprietary SEDDS technology capsules are designed for enhanced and rapid absorption of cannabinoids

Toronto — Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, has extended its existing strategic manufacturing agreement with Medipharm Labs Inc. for the commercialization of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems technology capsules for the Canadian and international markets.

“We are happy to be advancing our proprietary SEDDS technology capsules to the market with MediPharm, who have demonstrated focus, alignment and the necessary capabilities to manufacture and deliver these products across a number of markets and channels. We are excited about the potential of our proprietary single-dose formulations in both medical and pharmaceutical cannabinoid segments.” — Aras Azadian, CEO, Avicanna

Canadian commercialization under Good Production Practices (GPP)

Under the expanded Strategic Manufacturing Agreement, Avicanna intends to commercialize its proprietary SEDDS technology capsules, under the RHO Phyto brand, across domestic nation-wide medical channels including the Avicanna’s MyMedi.ca online cannabis care platform and MediPharm’s Canna farms platform. Additionally, MediPharm intends to commercialize the capsules across adult use wellness channels under its MediPharm Labs brand.

International and pharmaceutical potential under Good Manufacturing Practices (GMP)

MediPharm intends to manufacture these proprietary capsules in accordance with GMP standards to fulfill domestic and international pharmaceutical standards. The expanded strategic manufacturing agreement provides that each of Avicanna and MediPharm may take steps towards offering these products internationally through existing internal infrastructure and externally with parties under contract.